Switch theme
Sign up to access all valuation multiples
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing and maintaining the healthcare entities, wholesale medicines and retail of medical and surgical equipment, prosthetics and devices for the disabled, hospital equipment and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants and the packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Services/Medicine and Pharmaceutical products. The majority of the company's revenue is earned from the Medical service segment.
1994
n/a
LTM Revenue $925M
LTM EBITDA $196M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dallah Healthcare has a last 12-month revenue (LTM) of $925M and a last 12-month EBITDA of $196M.
In the most recent fiscal year, Dallah Healthcare achieved revenue of $856M and an EBITDA of $200M.
Dallah Healthcare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dallah Healthcare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $925M | XXX | $856M | XXX | XXX | XXX |
| Gross Profit | $925M | XXX | $322M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | $196M | XXX | $200M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $152M | XXX | $156M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $124M | XXX | $126M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $462M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dallah Healthcare's stock price is SAR 119 (or $32).
Dallah Healthcare has current market cap of SAR 12.0B (or $3.2B), and EV of SAR 13.8B (or $3.7B).
See Dallah Healthcare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.2B | XXX | XXX | XXX | XXX | $1.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dallah Healthcare has market cap of $3.2B and EV of $3.7B.
Dallah Healthcare's trades at 4.3x EV/Revenue multiple, and 18.4x EV/EBITDA.
Equity research analysts estimate Dallah Healthcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dallah Healthcare has a P/E ratio of 25.8x.
See valuation multiples for Dallah Healthcare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | 18.4x | XXX | XXX | XXX |
| EV/EBIT | 24.1x | XXX | 23.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.8x | XXX | 25.5x | XXX | XXX | XXX |
| EV/FCF | -3458.9x | XXX | 44.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDallah Healthcare's last 12 month revenue growth is 16%
Dallah Healthcare's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Dallah Healthcare's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dallah Healthcare's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dallah Healthcare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dallah Healthcare acquired XXX companies to date.
Last acquisition by Dallah Healthcare was XXXXXXXX, XXXXX XXXXX XXXXXX . Dallah Healthcare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dallah Healthcare founded? | Dallah Healthcare was founded in 1994. |
| Where is Dallah Healthcare headquartered? | Dallah Healthcare is headquartered in Saudi Arabia. |
| Is Dallah Healthcare publicy listed? | Yes, Dallah Healthcare is a public company listed on SAU. |
| What is the stock symbol of Dallah Healthcare? | Dallah Healthcare trades under 4004 ticker. |
| When did Dallah Healthcare go public? | Dallah Healthcare went public in 2012. |
| Who are competitors of Dallah Healthcare? | Similar companies to Dallah Healthcare include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Dallah Healthcare? | Dallah Healthcare's current market cap is $3.2B |
| What is the current revenue of Dallah Healthcare? | Dallah Healthcare's last 12 months revenue is $925M. |
| What is the current revenue growth of Dallah Healthcare? | Dallah Healthcare revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Dallah Healthcare? | Current revenue multiple of Dallah Healthcare is 4.0x. |
| Is Dallah Healthcare profitable? | Yes, Dallah Healthcare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dallah Healthcare? | Dallah Healthcare's last 12 months EBITDA is $196M. |
| What is Dallah Healthcare's EBITDA margin? | Dallah Healthcare's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Dallah Healthcare? | Current EBITDA multiple of Dallah Healthcare is 18.8x. |
| What is the current FCF of Dallah Healthcare? | Dallah Healthcare's last 12 months FCF is -$1.1M. |
| What is Dallah Healthcare's FCF margin? | Dallah Healthcare's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Dallah Healthcare? | Current FCF multiple of Dallah Healthcare is -3458.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
